Our Science – CCRNP Website
CCR Nanobiology Program
Selected News Items
|6th Annual Cancer Nanobiology Think Tank|
|Web Site: http://web.ncifcrf.gov/events/nanobiology/2011/default.asp|
|The 6th Annual Cancer Nanobiology Think Tank will be devoted to Triggered Nanoparticles from principles of triggering, design considerations to possible clinical applications and future directions. In particular, we plan to focus the discussion on currently available strategies, approaches, and mechanisms of triggered drug release from various nanoparticles. For the 6th Annual Cancer Nanobiology Think Tank, we have invited speakers who will bring their expertise to bear on the various facets of this theme. Brainstorming sessions focused around the talks, discussions, and questions that arise will follow their presentations. Participants are encouraged to submit abstracts related to the theme of the Think Tank and they will have the opportunity to present their studies in poster sessions during the day.
|Anu Puri Elected Co-Chair of the CCR Staff Scientis/Staff Clinician (SSSC) Organization|
|The mission of the CCR Staff Scientist/Staff Clinician (SSSC) Organization is to advance the professional goals and scientific careers of CCR Staff Scientists and Staff Clinicians.
Election results are in!!! Our new officers are:
2011-2012 co-chairs: Anu Puri, Christopher Marchand and Marybeth Hughes.
2011-2012 secretaries: Jianbo Chen and Christina Stuelten.
Congratulations to our new officers!!! They will take office in Jan 2011 and serve for two years.
|JMB Top Cited Article 2008 - 2010|
|Journal of Molecular Biology
Top Cited Article 2008 - 2010
Awarded to: Tsai, C.-J., del Sol, A., Nussinov R.
For the paper entitled, "Allostery: Absence of a Change in Shape Does Not Imply that Allostery Is Not at Play"
This paper was published in: Journal of Molecular Biology, Volume 378, Issue 1, 2008.
|Blumenthal Group Publication Featured on Homepage of the American Society for Photobiology (ASP)|
|Web Site: http://www.photobiology.org|
|Recent publication, Characterization of the Effects of Aryl-azido Compounds and UVA featured on homepage of American Society for Photobiology
Belanger JM, Raviv Y, Viard M, de la Cruz MJ, Nagashima K, Blumenthal R (2010) Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type. Photochem Photobiol 86: 1099-1108
|Dr. Ruth Nussinov - 2011 Biophysical Society Fellow|
|Web Site: http://www.eurekalert.org/pub_releases/2010-09/bs-bsa090310.php|
|Biophysical Society announces 2011 society fellows
Valerie Daggett, University of Washington, for her technical innovations and improvements in the field of molecular dynamic simulation;
Donald M. Engelman, Yale University, for his substantial and highly influential contributions to the field of membrane structure and the interactions of lipid bilayers with proteins;
Jennifer Lippincott-Schwartz, NIH, for her groundbreaking advances in optical highlighter fluorescent protein technology and impact on the field of superresolution microscopy;
Ruth Nussinov, NIH, for her extraordinary contributions to advances in computational biology on both nucleic acids and proteins;
Lynne J. Regan, Yale University for her pioneering research in protein assembly, recognition, and design; and
Anthony Watts, University of Oxford, for his significant contributions to the understanding of membrane structure and dynamics involving lipids, proteins, and ligands.
|CCRNP Award Recipients: 2010 Spring Research Festival Poster Presentation Winners|
|The Role of Sodium and Magnesium ions Concentrations on HIV
MAL and LAI Kissing Loop Dimerization
Poster Category: Structural Biology & Chemistry
Light-Induced Permeability Changes in Liposomes Containing Photo-Polymerizable Phospholipids
Poster Category: Therapeutics and Drug Delivery
Cell specific targeting of lipid-based nanoparticles for
enhanced delivery of therapeutic agents
Poster Category: Therapeutics and Drug Delivery
|Press Release for Australia (where antibody from Dr. Dimitrov's group) was administered to mother and child|
|Child put on experimental Hendra drug
May 27, 2010 - 5:59PM
A Sunshine Coast mother and daughter at high risk of developing the Hendra virus have been given an experimental drug not tested on humans.
The move came as a 12th person who was in touch with an infected horse was tested for Hendra.
Initial blood testing has cleared 11 people after the infected horse was put down at a Tewantin property on May 17.
Rebecca Day and her daughter Mollie, 12, on Thursday took their first infusion of an experimental treatment, which arrived from the United States that morning, for the virus.
They are being monitored in Princess Alexandra Hospital in Brisbane.
Queensland Chief Health Officer Jeannette Young told reporters in Brisbane on Thursday the pair had "significant exposure" to the horse.
"There is a real risk that these people will go on to develop a full-blown Hendra infection and unfortunately, we know four of the seven people who have gone on to do that have died," Dr Young said.
"That's why we've made this offer to those two people."
The drug has prevented the Hendra virus in ferrets and monkeys, but it failed in a last-ditch bid to save the life of Rockhampton vet Alister Rodgers as he lay in a coma in 2009.
Dr Young said the appropriate time for its use was before symptoms occurred.
She says because there haven't been any human trials, it's not known if there will be any side-effects, but she believes there won't be any.
The drug's antibodies work by attaching themselves to the virus and blocking it from entering cells in small blood vessels.
Dr Young said there would be only one infusion and the mother and daughter would be monitored for 42 days.
The others had not been offered the treatment because they were not considered at high risk, she said.
|Alzheimer's treatment may promote neural cell death|
|Web Site: http://www.pnas.org/site/misc/selections_3_22_10.shtml#cell|
|PNAS Media Selection: Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R.
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6538-43.
|Two CCRNP Investigators Recognized for Top CCR Science Advances FY2009|
|Drs. Ruth Nussinov and Dimiter Dimitrov were given special recognition by CCR for basic science advances:
Advances in p53 - Cooperativity dominates the genomic organization of p53-response elements - submission by Ruth Nussinov
Advances in HIV prevention - Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers - submission by Dimiter Dimitrov
|Gene Therapy Method Slows Tumor Growth in Mice|
|Web Site: http://www.cancer.gov/newscenter/pressreleases/SuicideGeneNewsNote|
|NCI researchers have developed a novel method in mice of delivering genes to cancer cells, that when expressed, promote cell death. These genes, known as suicide genes, cause a cell to kill itself through a process known as apoptosis. The new technique uses the survivin gene promoter to express the suicide gene and induce apoptosis in cancer cells. This method of gene delivery effectively targeted tumor cells with a minimum effect on normal cells. (see full news note at the above link)|
|Scientists Report Major Advance in a Human Antibody Therapy against the Deadly Nipah Virus|
|Web Site: http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000642|
|A collaborative research team from the Uniformed Services University of the Health Sciences (USU), the Australian Animal Health Laboratory (AAHL), and the National Cancer Institute (NCI), National Institutes of Health (NIH) reports a major step forward in the development of an effective therapy against two deadly viruses. Nipah virus and the related Hendra virus are found in Pteropid fruit bats (flying foxes) and are characterized by their recent emergence as agents capable of causing illness and death in domestic animals and humans.|
|The 1st Joint U.S.-China Symposium on Nanobiology and Nanomedicine - October 21-23, 2008|
|Web Site: http://www.china-us-nanobiomed-conf.org/|
|The idea for this exciting collaboration originated in generative scientific exchanges between Dr. Xing-Jie Liang, Director, Nano-Medicine and Nano-Biotechnology Laboratory at the National Center for Nanoscience and Technology, in Beijing, China, and Dr. Robert Blumenthal, Director of the Center for Cancer Research Nanobiology Program, National Cancer Institute, National Institutes of Health, in Frederick, Maryland, U.S.A. Together, Drs. Liang and Blumenthal helped developed the vision for this trans-national symposium, secured support and established a Steering Committee of senior Chinese and U.S. scientists.
The National Institutes of Health (NIH) and the Trans-NIH Nanotechnology Task Force, co-sponsored the first Joint U.S.-China Symposium on Nanobiotechnology and Nanomedicine, in Beijing on October 21-23, 2008. The goal was to develop and apply nanotechnology to prevent, detect, diagnose and treat disease, and to consider the effect of exposure to nanomaterials on workers, the general public and the environment. The initial dialogue comprised an important first step in sharing information, scientific brainstorming, and the development of mutually productive collaborations and working relationships between Chinese and American scientists. This activity fell under the Science & Technology bilateral agreement between the U.S. and China
|CCRNP Award Recipient - Dr. Dimiter Dimitrov|
|Web Site: http://videocast.nih.gov/summary.asp?live=8134|
|Dr. Dimitrov was selected as a 2009 NCI Outstanding Mentor. This award will be presented at the NCI Director Awards Ceremony on Tuesday, October 20th|
This page was last updated on 4/28/2011.